Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.
With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions.
Details on the vote results are available on the Company's website.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 hours ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
9 hours ago
- Yahoo
Is PepsiCo Still a Refreshing Buy?
Sales growth has been anemic. The board of directors recently increased the dividend by 5%. The share price drop has created a better valuation. 10 stocks we like better than PepsiCo › PepsiCo (NASDAQ: PEP) has become a household name. In fact, it's likely you have at least one of the company's products in your home right now. However, investors need to consider more than the ubiquity of a company's product before purchasing the stock. You should analyze a company's prospects before committing to an investment. It's particularly imperative when the shares have dropped by quite a bit. In the case of PepsiCo, the stock has fallen about 23% over the last year through June 3. It's time to take a closer look at PepsiCo to see if the market has overreacted to short-term concerns or whether the drop is foretelling long-term issues. PepsiCo sells its beverages and food items under brands like Pepsi, Gatorade, and Quaker. However, even this large consumer staples company isn't immune from larger economic forces. First-quarter revenue only grew about 1% compared to a year ago. Price increases contributed 3 percentage points but lower volume subtracted 2 percentage points. The company adjusted these figures to exclude foreign-currency translation effects and the impact of acquisitions and divestitures. On an adjusted basis, operating profitability dropped 1%. Certainly, those numbers aren't very encouraging, and volume has been weak for some time. Investors would like to see higher volume driving faster revenue growth. However, it's important to remember that consumers have been weary from persistently high inflation that has squeezed their wallets, and tariffs add another level of uncertainty. Management noted the economic challenges when projecting a low-single-digit percentage increase in revenue this year and flat earnings per share compared to 2024. However, these short-term global economic factors don't change my optimistic view about PepsiCo's long-term prospects given its powerful brands. At some point, prices will stabilize and people will return to their more normal purchasing habits. When they do, it's hard to imagine they won't reach for a bottle of soda or chips sold under PepsiCo's umbrella. If you like dividends, PepsiCo fits the bill. In fact, the company has built quite a track record. The board of directors raised the company's quarterly dividend by 5%, starting in June. The new quarterly rate is $1.4225, or $5.69 annually. It's also a strong indication of management's and the board's confidence in PepsiCo's future. Impressively, that marked 53 consecutive years with a dividend increase. That makes PepsiCo a Dividend King, which is a group of companies that have raised payouts for at least 50 years. At the new annual dividend rate, the stock has a 4.3% dividend yield. That's much higher than the S&P 500 index's 1.3%. Aside from its impressive track record and recent increase, PepsiCo can afford the dividends when looking at objective measures like the 78% payout ratio. PepsiCo's sharp stock decline has resulted in a better valuation. Its price-to-earnings (P/E) ratio has fallen from 27 to 19. Of course, tepid sales and earnings growth will drive down a stock price and P/E ratio. While PepsiCo may never achieve rapid growth, the company should see a higher pace of revenue and earnings gains when broader economic policies return to a more normal state and consumers feel more comfortable spending money. What should investors do? While investors looking for pure growth stocks may find better alternatives, if you're interested in dividends, PepsiCo makes a good choice. That's based on the stock's attractive yield and commitment to regular increases. Additionally, patient investors should benefit from a higher share price. The prospect of an attractive total return adds up to a buying opportunity for those willing to wait for better economic times. Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Is PepsiCo Still a Refreshing Buy? was originally published by The Motley Fool Sign in to access your portfolio
Associated Press
11 hours ago
- Associated Press
Empress Grants Stock Options and Equity Incentives
VANCOUVER, BC / ACCESS Newswire / June 6, 2025 / Empress Royalty Corp. (TSXV:EMPR)(OTCQX:EMPYF) ('Empress Royalty' or the 'Company') announces that the Board of Directors has approved the granting of 1,400,000 incentive stock options (the 'Options') to purchase an aggregate of 1,400,000 common shares (the 'CommonShares') of the Company to certain directors, officers, employees, and consultants of the Company. Each Option is exercisable into one Common Share at an exercise price of $0.68, being the closing market price of Empress' common shares on June 6, 2025. The Options will vest as to one-third on the date of grant, one-third one year from the date of grant, and one-third two years from the date of grant and will expire on June 6, 2030. All stock option grants will be governed by the Company's Stock Option Plan which was approved by the shareholders of the Company at its last annual meeting of shareholders held on June 26, 2024. In addition, the Board of Directors has also approved the granting of 1,750,000 restricted share units ('RSUs') and 650,000 deferred share units ('DSUs') to certain directors, officers and consultants of the Company. Each of the RSUs and DSUs will vest equally over two years, with the first vesting date occurring June 6, 2026. Upon vesting, each RSU and DSU represents the right to receive one common share in the capital of the Company in accordance with the Company's Equity Incentive Plan, which was last approved by the shareholders of the Company at its annual meeting of shareholders held on September 28, 2022. ABOUT EMPRESS ROYALTY CORP. Empress is a global royalty and streaming creation company providing investors with a diversified portfolio of gold and silver investments. Empress has built a portfolio of precious metal investments and is actively investing in mining companies with development and production stage projects who require additional non-dilutive capital. The Company has strategic partnerships with Endeavour Financial and Terra Capital which allow Empress to not only access global investment opportunities but also bring unique mining finance expertise, deal structuring and access to capital markets. Empress is looking forward to continuously creating value for its shareholders through the proven royalty and streaming models. ON BEHALF OF EMPRESS ROYALTY CORP. Per: Alexandra Woodyer Sherron, CEO and President For further information, please visit our website at or contact us by email at [email protected] or by phone at +1.604.331.2080. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. The information contained herein includes 'forward-looking statements' and 'forward looking information' as defined under applicable Canadian securities laws ('forward-looking statements'). Forward-looking statements and information can generally be identified by the use of terms such as 'may', 'will', 'should', 'expect', 'intend', 'estimate' ,"continue', 'believe', 'plans', 'anticipate' or similar terms. Forward-looking information and statements include, but are not limited to, statements with respect to the activities, events or developments that Empress Royalty Corp. ('Empress' or the 'Company') expects or anticipates will or may occur in the future, including those regarding future growth and ability to create new streams or royalties, the development and focus of the Company , its acquisition strategy, the plans and expectations of the operators of the projects underlying its interests, including the proposed advancement and expansion of such projects; the results of exploration, development and production activities of the operators of such projects; and the Company's expectations regarding future revenues. Forward-looking information and statements are based on the then current expectations, beliefs, assumptions, estimates and forecasts about Empress's business and the industry and markets in which it operates. Forward-looking information and statements are made based upon numerous assumptions and although the assumptions made by the Company in providing forward-looking information and statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate. Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual results, performances and achievements of Empress to differ materially from any projections of results, performances and achievements of Empress including, without limitation, any inability of the operators of the properties underlying the Company's royalty and stream interests to execute proposed plans for such properties or to achieve planned development and production estimates and goals, risks related to the operators of the projects in which the Company holds interests, including the successful continuation of operations at such projects by those operators, risks related to exploration, development, permitting, infrastructure, operating or technical difficulties on any such projects, risks related to international operations, government relations and environmental regulation, uncertainty relating to the availability and costs of financing needed in the future and the Company's ability to carry out its growth plans as well as the impact of the COVID-19 pandemic and other related risks and uncertainties. For a discussion of important factors which could cause actual results to differ from forward-looking statements, refer to the annual information form of Empress for the year ended December 31, 2024 and its other publicly filed documents under its profile at . Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and statements, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information and statements. The Company undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws. Disclosure relating to properties in which Empress holds royalty or stream interests is based on information publicly disclosed by the owners or operators of such properties. The Company generally has limited or no access to the properties underlying its interests and is largely dependent on the disclosure of the operators of its interests and other publicly available information. The Company generally has limited or no ability to verify such information. Although the Company does not have any knowledge that such information may not be accurate, there can be no assurance that such third-party information is complete or accurate. In addition, certain information publicly reported by operators may relate to a larger property than the area covered by the Company's interest, which often may only apply to a portion of the overall project area or applicable mineral resources or reserves. SOURCE: Empress Royalty Corp. press release
